Home' Australian Pharmacist : Australian Pharmacist July 2012 Contents Australian Pharmacist July 2012 I ©Pharmaceutical Society of Australia Ltd. 577
Continuing Professional Development
Submit your answers online at www.psa.org.au and receive automatic feedback
1. Which of the following statements is
a) The in ammation is con ned to the
small intestine in Crohn's disease,
while it can extend throughout the
length of the gastrointestinal tract in
in ammatory bowel disease.
b) The in ammation is con ned to
the colon in Crohn's disease, while
ulcerative colitis may occur anywhere
in the gastrointestinal tract.
c) The in ammation in Crohn's disease
a ects the mucosal layer, while the
in ammation in ulcerative colitis may
extend through the length of the
d) The in ammation is con ned to the
colon in ulcerative colitis while in
Crohn's disease it may occur anywhere
in the gastrointestinal tract.
2. Which statement pertaining to
in ammatory bowel disease is
a) Crohn's disease and in ammatory
bowel disease are common types of
b) In ammatory bowel disease may
cause changes to the microorganisms
colonising the colon.
d) Mesalazine must always be used as
d) Surgery is routinely recommended in
the management of IBD.
3. Which is not a general aim of
pharmacological treatment for IBD?
a) Alleviate symptoms and induce
b) Prevent complications and nutritional
c) Maintain remission and quality of life.
d) Provide a curative treatment.
4. The 'top down' philosophy is one
of the approaches used to manage
in ammatory bowel disease.
Which statement pertains to this
a) The 'top down' philosophy is only for
the management of Crohn's disease.
b) More potent and aggressive therapies
should only be used after the less toxic
aminosalicylates and corticosteroids
become ine ective.
c) Resistance to treatment, complications
and surgery might be avoided by
using the more potent and aggressive
treatments from the start when the
condition is more responsive to
d) Patients managed using the 'top
down' philosophy can end up being
on therapy that does not e ectively
treat the in ammation for prolonged
periods of time, leading to a delay in
starting stronger therapies.
5. Some delivery systems used to
target the delivery of therapeutic
agents to the colon attempt to
exploit the conditions that are
unique to the colon. Which is NOT
one of these systems?
a) Pressure based delivery systems.
b) Microbial dependent delivery systems.
c) Temperature controlled delivery
d) pH dependent delivery systems.
A score of 4 out of 5 attracts 1.5 CPD credits.
Submit your answers online before
1 September 2012 at www.psa.org.
au and receive automatic feedback, or
PSA CPD answers
Pharmaceutical Society of Australia,
Level 1, 381 Royal Parade,
PARKVILLE VIC 3052
Fax: (03) 9389 4044
NZCP CPD answers,
PO Box 11 640,
Fax: (04) 381 4786
Australian Pharmacist Continuing Professional
Development (CPD) is a central element of PSA's
CPD&PI program. It is also part of the New Zealand
College of Pharmacists (NZCP) education program
for NZ pharmacists.
The CPD section is recognised under the PSA
CPD&PI program as a Group 2 activity. Members
can choose which articles they want to answer
questions on and get CPD credits based on the
questions they answer. The credits allocated to
each section and the pass mark are shown with
CPD credits are allocated based on the length of
the article and the complexity of the information
presented. A minimum of 6 out of 8 questions, 4
out of 5 questions, or 3 out of 4 questions correct is
required for the allocation of Group 2 CPD Credits.
If not submitting online, write the correct answers
in the spaces provided on the answer panel on
the back of the address sheet, ll in your name,
member number and address details, then either
mail or fax the answer page to the relevant
address and fax number for marking.
PSA members can answer online at
www.psa.org.au and receive automatic feedback.
• You will need to login to submit your answers
online. If you do not have member access
details, you can request them via a link from
the login page.
• Select Pharmacist Members from the blue, left
hand side menu.
• Select Submit Answers.
• Select Australian Pharmacist CPD.
unique colon-specific drug delivery system (CODESTM). Pharm
25. Li J, Yang L, Ferguson SM, et al. In vitro evaluation of dissolution
behaviour for a colon-specific drug delivery system (CODESTM)
in multi-pH media using United States Pharmacopeia
Apparatus II and III. AAPS PharmSciTech. 2002;3(4):59--67.
26. Ravi V, Pramod Kumar TM, Siddaramaiah. Novel colon targeted
drug delivery system using natural polymers. Indian J Pharm
27. Canny GO, McCormick BA. Bacteria in the intestine,
helpful residents or enemies from within. Infect Immun.
28. Metz T, Jones ML, Chen H, et al. A new method for targeted
drug delivery using polymeric microcapsules. Cell Biochem
29. Shukla R, Cheryan M. Zein: the industrial protein from corn. Ind
Crops Prod. 2001;13(3):171--92.
30. Singh N, Georget DMR, Belton PS, Barker SA. Physical properties
of zein films containing salicylic acid and acetyl salicylic acid. J
Cereal Sci. 2010;52(2):282--87.
31. Fu TJ, Abbott UR, Hatzos C. Digestibility of food allergens and
nonallergenic proteins in simulated gastric fluid and simulated
intestinal fluid - a comparative study. J Agric Food Chem.
32. Liu X, Sun Q, Wang H, Zhang L, Wang J. Microspheres of
corn protein, zein, for an ivermectin drug delivery system.
33. Georget DMR, Barker SA, Belton PS. A study on maize proteins
as a potential new tablet excipient. Eur J Pharm Biopharm.
34. Parris N, Cooke P, Hicks K. Encapsulation of essential oils in zein
nanospherical particles. J Agric Food Chem. 2005;53(12):4788--
35. Lau ETL, Johnson SK, Mikkelsen D, Halley PJ, Steadman KJ.
Preparation and in vitro release of zein microparticles loaded
with prednisolone for oral delivery. J Microencapsul. 2012;29:In
36. Wang HJ, Lin ZX, Liu XM, Sheng SY, Wang JY. Heparin-loaded
zein microsphere film and hemocompatibility. J Control
Links Archive Australian Pharmacist June 2012 Australian Pharmacist August 2012 Navigation Previous Page Next Page